12/8/2005

The studies cited TAP Pharmaceutical Products' febuxostat, which is awaiting U.S. approval, as showing promise against gout while Centocor's infliximab was shown to sharply reduce bloody diarrhea, abdominal cramps and other symptoms associated with ulcerative colitis. Infliximab is sold as Remicade for arthritis and Crohn's disease.

Related Summaries